Euvichol or Euvichol-Plus Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited treatment options for cholestasis, increasing prevalence of gallstone disease, early adoption of udca therapy, growing awareness of pbc management, clinical validation of bile acid therapies.

The growth in the forecast period can be attributed to rising incidence of nafld, expanding liver disease screening programs, growing demand for combination liver therapies, improved access to hepatology care, increasing healthcare spending on chronic diseases. Major trends in the forecast period include growing adoption of udca-based liver therapies, rising use in cholestatic liver disorders, combination therapies for enhanced liver protection, increasing diagnosis of chronic liver diseases, expansion of preventive liver care programs.

The increasing prevalence of liver diseases is expected to drive the growth of the euvichol or euvichol-plus market in the coming years. Liver diseases encompass a variety of medical conditions that impair the liver’s ability to function properly. The rise in liver diseases is primarily attributed to increasing obesity rates, which contribute to non-alcoholic fatty liver disease, and excessive alcohol consumption, a major factor in alcoholic liver disease. Euvichol and Euvichol-Plus are used to manage liver-related conditions, particularly chronic hepatitis B, by supporting liver function, reducing inflammation, and improving liver cell membrane integrity. For example, in April 2024, GOV.UK, a UK-based government agency, reported that hospital admission rates for liver disease rose to 155.2 per 100,000 population in the financial year ending 2023, up from 150.6 per 100,000 in 2022. Therefore, the growing prevalence of liver diseases is driving the expansion of the euvichol or euvichol-plus market.

The rise in healthcare expenditure is also anticipated to support the growth of the euvichol or euvichol-plus market. Healthcare expenditure encompasses total spending on healthcare services, including hospital care, pharmaceuticals, medical research, public health programs, and related services. The increase in healthcare expenditure is driven by factors such as an aging population, higher prevalence of chronic diseases, medical technology advancements, and rising treatment costs. This investment facilitates broader access to Euvichol and Euvichol-Plus, strengthening cholera prevention efforts among vulnerable populations. For example, in May 2024, a report by the Office for National Statistics, a UK-based government agency, indicated that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a 0.9% increase in 2022. Therefore, rising healthcare expenditure is driving the expansion of the euvichol or euvichol-plus market.

A notable trend in the euvichol or euvichol-plus market is the development of technologically advanced solutions, such as oral cholera vaccines, to address critical healthcare needs. Oral cholera vaccines are administered by mouth to prevent cholera, a bacterial infection that causes severe diarrhea and dehydration. For instance, in May 2023, Techinvention Lifecare Pvt. Ltd., an India-based biotechnology company, launched Euvichol-Plus, the first oral cholera vaccine packaged in a low-density polyethylene (LDPE) unidose pack. This innovative packaging improves usability and safety by reducing breakage and wastage commonly associated with traditional glass vials. Approved by the Central Drugs Standard Control Organization (CDSCO) after a successful phase III clinical trial, Euvichol-Plus addresses a major public health need in India, where nearly 400 million people are at risk of cholera. The vaccine is expected to enhance distribution during emergencies and humanitarian crises, supporting global efforts to eradicate cholera by 2030.

Major companies operating in the euvichol or euvichol-plus market are Eubiologics Co. Ltd., Techinvention Lifecare Pvt. Ltd.

North America was the largest region in the euvichol or euvichol-plus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the euvichol or euvichol-plus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the euvichol or euvichol-plus market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the euvichol or euvichol-plus market by increasing the cost of importing active pharmaceutical ingredients and formulation excipients used in udca-based therapies. These effects are more pronounced in hospital and clinic distribution channels across regions dependent on pharmaceutical imports such as asia pacific and latin america. Higher input costs can influence pricing strategies and public health procurement budgets. At the same time, tariffs are encouraging local manufacturing, regional sourcing of raw materials, and long term supply chain stability for liver disease medications.

The euvichol or euvichol-plus market research report is one of a series of new reports that provides euvichol or euvichol-plus market statistics, including euvichol or euvichol-plus industry global market size, regional shares, competitors with a euvichol or euvichol-plus market share, detailed euvichol or euvichol-plus market segments, market trends and opportunities, and any further data you may need to thrive in the euvichol or euvichol-plus industry. This euvichol or euvichol-plus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Euvichol and Euvichol-Plus are pharmaceutical products primarily used to manage liver diseases, particularly those related to cholestasis, gallstones, and primary biliary cirrhosis (PBC). Both are ursodeoxycholic acid (UDCA)-based treatments, with Euvichol-Plus offering a combination therapy.

The main products in this category are euvichol or euvichol-plus. Euvichol is an oral cholera vaccine mainly used to prevent cholera in endemic regions or during outbreaks. Its clinical applications include non-alcoholic fatty liver disease (NAFLD), liver dysfunction, and liver detoxification and protection. These products are distributed through hospitals, clinics, pharmacies, and public health campaigns.

The euvichol or euvichol-plus market consists of sales of products including ursofalk, actigall, and generic ursodeoxycholic acid (UDCA) formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.